Enable JavaScript to ensure website accessibility
Precipio Expands ICE COLD-PCR™ Menu For Breast, Colon And Endometrial Cancers

Ultra-sensitive assays for PIK3CA exons 9 & 20 detect mutations that impact critical therapeutic decisions [...]

Innovation Behind Precipio’s ICE-COLD PCR™ Platform Spotlighted In Media

Articles Highlight Scientific and Economic Advantages Provided by Precipio’s Technology NEW HAVEN, CT, (October 18th, [...]

Precipio Launches HemeScreen™, A Disruptive, Proprietary Molecular Test For Hematologic Cancers

Impacts a $100M annual US laboratory market by reducing testing costs through a simple, screening [...]

Precipio Granted 180 Day NASDAQ Extension To Regain Compliance

Enables Company to execute on strategic and commercial initiatives with the goal of meeting the [...]

Precipio Expands ICE-COLD PCR™ Lung Cancer Mutation Detection Offering

New reagent examines most relevant EGFR exons that impact therapeutic decisions for lung cancer patients [...]

Precipio Announces Third Quarter 2018 Revenues Estimated At 2.4 Times Year-Over-Year Q3-2017

Fourth consecutive Quarter of Triple-Digit YoY Quarterly Growth; Triple YTD Revenues Over Same Period Last [...]

Precipio Reminds Investors Of Conference Call With Management For Corporate Update And Second Quarter Results

Provides participation details for Thursday, August 23 call NEW HAVEN, CT, (August 22nd, 2018) – Specialty [...]

Precipio Announces Second Quarter 2018 Financial Results And Provides Corporate Update

Conference call with management to be held Thursday August 23, 2018 at 09:00 Eastern Time [...]

Precipio Appoints New Board Member To Replace Departing Director

Kathy LaPorte brings 30-year track record of VC success financing and operating innovative biopharma, diagnostics [...]

Precipio Announces 213% Year-Over-Year Revenue Growth In Preliminary Q2-2018 Results

Third consecutive quarter of triple-digit YoY Quarterly growth NEW HAVEN, CT, (July 18th, 2018) – Specialty [...]